靶向IGF2BP3增强menin-MLL抑制在MLL-AF4白血病中的抗白血病效应
本研究在体外和体内探讨靶向IGF2BP3与menin-MLL抑制联合对MLL-AF4驱动白血病的作用,采用CRISPR-Cas9介导的Igf2bp3缺失和小分子MI-503等抑制剂。结果显示Igf2bp3缺失使白血病细胞对menin-MLL抑制更敏感,联合作用增强抗白血病效应并促进分化。
要点
- Igf2bp3缺失使MLL-AF4白血病细胞对menin-MLL抑制在细胞生长和白血病起始细胞方面更敏感。
- Igf2bp3缺失和menin-MLL抑制均在体外和体内促进分化。
- IGF2BP3敲低联合menin-MLL抑制显示增强的抗白血病效应。
核心结论
- IGF2BP3是MLL-AF4介导白血病发生的致癌增强因子和有效治疗靶点,为在转录和转录后水平靶向白血病提供范式。
研究设计与样本
- 体外和体内研究,使用CRISPR-Cas9介导的Igf2bp3缺失进行遗传抑制,并使用多种市售抑制剂进行menin-MLL相互作用的药理学抑制。
主要发现
- Igf2bp3缺失使MLL-AF4白血病对menin-MLL抑制在体外对细胞生长和白血病起始细胞的作用更敏感。
- Igf2bp3缺失和menin-MLL抑制均在体外和体内导致分化增加,见功能读数与基因表达分析。
- IGF2BP3敲低在增加生存和减轻疾病方面比单独使用小分子MI-503药理学抑制menin-MLL效果更大,联合时显示增强的抗白血病效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RNA-binding proteins (RBPs) are emerging as a novel class of therapeutic targets in cancer, including in leukemia, given their important role in posttranscriptional gene regulation, and have the unexplored potential to be combined with existing therapies. The RBP insulin-like growth factor 2 messenger RNA-binding protein 3 (IGF2BP3) has been found to be a critical regulator of MLL-AF4 leukemogenesis and represents a promising therapeutic target. Here, we study the combined effects of targeting IGF2BP3 and menin-MLL interaction in MLL-AF4-driven leukemia in vitro and in vivo, using genetic inhibition with CRISPR-Cas9-mediated deletion of Igf2bp3 and pharmacologic inhibition of the menin-MLL interaction with multiple commercially available inhibitors. Depletion of Igf2bp3 sensitized MLL-AF4 leukemia to the effects of menin-MLL inhibition on cell growth and leukemic initiating cells in vitro. Mechanistically, we found that both Igf2bp3 depletion and menin-MLL inhibition led to increased differentiation in vitro and in vivo, seen in functional readouts and by gene expression analyses. IGF2BP3 knockdown had a greater effect on increasing survival and attenuating disease than pharmacologic menin-MLL inhibition with small molecule MI-503 alone and showed enhanced antileukemic effects in combination. Our work shows that IGF2BP3 is an oncogenic amplifier of MLL-AF4-mediated leukemogenesis and a potent therapeutic target, providing a paradigm for targeting leukemia at both the transcriptional and posttranscriptional level.
引用
- Lin TL, Jaiswal AK, Ritter AJ, et al. Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia. Blood Adv. 2024. PMID: 38048400. doi:10.1182/bloodadvances.2023011132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。